Literature DB >> 25710913

Specific roles of each TCR hemichain in generating functional chain-centric TCR.

Munehide Nakatsugawa1, Yuki Yamashita1, Toshiki Ochi1, Shinya Tanaka2, Kenji Chamoto1, Tingxi Guo3, Marcus O Butler4, Naoto Hirano5.   

Abstract

TCRα- and β-chains cooperatively recognize peptide-MHC complexes. It has been shown that a "chain-centric" TCR hemichain can, by itself, dictate MHC-restricted Ag specificity without requiring major contributions from the paired TCR counterchain. Little is known, however, regarding the relative contributions and roles of chain-centric and its counter, non-chain-centric, hemichains in determining T cell avidity. We comprehensively analyzed a thymically unselected T cell repertoire generated by transducing the α-chain-centric HLA-A*02:01(A2)/MART127-35 TCRα, clone SIG35α, into A2-matched and unmatched postthymic T cells. Regardless of their HLA-A2 positivity, a substantial subset of peripheral T cells transduced with SIG35α gained reactivity for A2/MART127-35. Although the generated A2/MART127-35-specific T cells used various TRBV genes, TRBV27 predominated with >10(2) highly diverse and unique clonotypic CDR3β sequences. T cells individually reconstituted with various A2/MART127-35 TRBV27 TCRβ genes along with SIG35α possessed a wide range (>2 log orders) of avidity. Approximately half possessed avidity higher than T cells expressing clone DMF5, a naturally occurring A2/MART127-35 TCR with one of the highest affinities. Importantly, similar findings were recapitulated with other self-Ags. Our results indicate that, although a chain-centric TCR hemichain determines Ag specificity, the paired counterchain can regulate avidity over a broad range (>2 log orders) without compromising Ag specificity. TCR chain centricity can be exploited to generate a thymically unselected Ag-specific T cell repertoire, which can be used to isolate high-avidity antitumor T cells and their uniquely encoded TCRs rarely found in the periphery because of tolerance.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25710913      PMCID: PMC4369446          DOI: 10.4049/jimmunol.1401717

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  85 in total

1.  Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity.

Authors:  Naoto Hirano; Marcus O Butler; Zhinan Xia; Sascha Ansén; Michael S von Bergwelt-Baildon; Donna Neuberg; Gordon J Freeman; Lee M Nadler
Journal:  Blood       Date:  2005-10-20       Impact factor: 22.113

2.  Class II-restricted T cell receptor engineered in vitro for higher affinity retains peptide specificity and function.

Authors:  K Scott Weber; David L Donermeyer; Paul M Allen; David M Kranz
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-19       Impact factor: 11.205

Review 3.  New experimental approaches in retrovirus-mediated expression screening.

Authors:  T Kitamura
Journal:  Int J Hematol       Date:  1998-06       Impact factor: 2.490

4.  Directed evolution of human T-cell receptors with picomolar affinities by phage display.

Authors:  Yi Li; Ruth Moysey; Peter E Molloy; Anne-Lise Vuidepot; Tara Mahon; Emma Baston; Steven Dunn; Nathaniel Liddy; Jansen Jacob; Bent K Jakobsen; Jonathan M Boulter
Journal:  Nat Biotechnol       Date:  2005-02-20       Impact factor: 54.908

5.  Directed evolution of human T cell receptor CDR2 residues by phage display dramatically enhances affinity for cognate peptide-MHC without increasing apparent cross-reactivity.

Authors:  Steven M Dunn; Pierre J Rizkallah; Emma Baston; Tara Mahon; Brian Cameron; Ruth Moysey; Feng Gao; Malkit Sami; Jonathan Boulter; Yi Li; Bent K Jakobsen
Journal:  Protein Sci       Date:  2006-04       Impact factor: 6.725

6.  Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness.

Authors:  Melita Irving; Vincent Zoete; Michael Hebeisen; Daphné Schmid; Petra Baumgartner; Philippe Guillaume; Pedro Romero; Daniel Speiser; Immanuel Luescher; Nathalie Rufer; Olivier Michielin
Journal:  J Biol Chem       Date:  2012-05-01       Impact factor: 5.157

Review 7.  MM-GBSA binding free energy decomposition and T cell receptor engineering.

Authors:  V Zoete; M B Irving; O Michielin
Journal:  J Mol Recognit       Date:  2010 Mar-Apr       Impact factor: 2.137

8.  Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR.

Authors:  Sachiko Okamoto; Junichi Mineno; Hiroaki Ikeda; Hiroshi Fujiwara; Masaki Yasukawa; Hiroshi Shiku; Ikunoshin Kato
Journal:  Cancer Res       Date:  2009-11-10       Impact factor: 12.701

9.  Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.

Authors:  Richard A Morgan; Nachimuthu Chinnasamy; Daniel Abate-Daga; Alena Gros; Paul F Robbins; Zhili Zheng; Mark E Dudley; Steven A Feldman; James C Yang; Richard M Sherry; Giao Q Phan; Marybeth S Hughes; Udai S Kammula; Akemi D Miller; Crystal J Hessman; Ashley A Stewart; Nicholas P Restifo; Martha M Quezado; Meghna Alimchandani; Avi Z Rosenberg; Avindra Nath; Tongguang Wang; Bibiana Bielekova; Simone C Wuest; Nirmala Akula; Francis J McMahon; Susanne Wilde; Barbara Mosetter; Dolores J Schendel; Carolyn M Laurencot; Steven A Rosenberg
Journal:  J Immunother       Date:  2013-02       Impact factor: 4.456

10.  T-cell receptor specificity maintained by altered thermodynamics.

Authors:  Florian Madura; Pierre J Rizkallah; Kim M Miles; Christopher J Holland; Anna M Bulek; Anna Fuller; Andrea J A Schauenburg; John J Miles; Nathaniel Liddy; Malkit Sami; Yi Li; Moushumi Hossain; Brian M Baker; Bent K Jakobsen; Andrew K Sewell; David K Cole
Journal:  J Biol Chem       Date:  2013-05-22       Impact factor: 5.157

View more
  19 in total

1.  Optimization of T-cell Reactivity by Exploiting TCR Chain Centricity for the Purpose of Safe and Effective Antitumor TCR Gene Therapy.

Authors:  Toshiki Ochi; Munehide Nakatsugawa; Kenji Chamoto; Shinya Tanaka; Yuki Yamashita; Tingxi Guo; Hiroshi Fujiwara; Masaki Yasukawa; Marcus O Butler; Naoto Hirano
Journal:  Cancer Immunol Res       Date:  2015-05-05       Impact factor: 11.151

2.  Affinity-matured HLA class II dimers for robust staining of antigen-specific CD4+ T cells.

Authors:  Kenji Sugata; Yukiko Matsunaga; Yuki Yamashita; Munehide Nakatsugawa; Tingxi Guo; Levon Halabelian; Yota Ohashi; Kayoko Saso; Muhammed A Rahman; Mark Anczurowski; Chung-Hsi Wang; Kenji Murata; Hiroshi Saijo; Yuki Kagoya; Dalam Ly; Brian D Burt; Marcus O Butler; Tak W Mak; Naoto Hirano
Journal:  Nat Biotechnol       Date:  2021-03-01       Impact factor: 54.908

3.  Key Residues at Third CDR3β Position Impact Structure and Antigen Recognition of Human Invariant NK TCRs.

Authors:  Kenji Chamoto; Tingxi Guo; Stephen W Scally; Yuki Kagoya; Mark Anczurowski; Chung-Hsi Wang; Muhammed A Rahman; Kayoko Saso; Marcus O Butler; Priscilla P L Chiu; Jean-Philippe Julien; Naoto Hirano
Journal:  J Immunol       Date:  2016-12-21       Impact factor: 5.422

Review 4.  Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics.

Authors:  Abhishek D Garg; Sanket More; Nicole Rufo; Odeta Mece; Maria Livia Sassano; Patrizia Agostinis; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-10-04       Impact factor: 8.110

5.  A Subset of Human Autoreactive CD1c-Restricted T Cells Preferentially Expresses TRBV4-1+ TCRs.

Authors:  Tingxi Guo; Ming Yin Koo; Yuki Kagoya; Mark Anczurowski; Chung-Hsi Wang; Kayoko Saso; Marcus O Butler; Naoto Hirano
Journal:  J Immunol       Date:  2017-12-13       Impact factor: 5.422

6.  CDR3β sequence motifs regulate autoreactivity of human invariant NKT cell receptors.

Authors:  Kenji Chamoto; Tingxi Guo; Osamu Imataki; Makito Tanaka; Munehide Nakatsugawa; Toshiki Ochi; Yuki Yamashita; Akiko M Saito; Toshiki I Saito; Marcus O Butler; Naoto Hirano
Journal:  J Autoimmun       Date:  2015-12-31       Impact factor: 7.094

7.  BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models.

Authors:  Yuki Kagoya; Munehide Nakatsugawa; Yuki Yamashita; Toshiki Ochi; Tingxi Guo; Mark Anczurowski; Kayoko Saso; Marcus O Butler; Cheryl H Arrowsmith; Naoto Hirano
Journal:  J Clin Invest       Date:  2016-08-22       Impact factor: 14.808

8.  Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy.

Authors:  Takemasa Tsuji; Akira Yoneda; Junko Matsuzaki; Anthony Miliotto; Courtney Ryan; Richard C Koya; Kunle Odunsi
Journal:  Cancer Immunol Res       Date:  2018-03-27       Impact factor: 11.151

9.  Direct measurement of T cell receptor affinity and sequence from naïve antiviral T cells.

Authors:  Shu-Qi Zhang; Patricia Parker; Ke-Yue Ma; Chenfeng He; Qian Shi; Zhonghao Cui; Chad M Williams; Ben S Wendel; Amanda I Meriwether; Mary Alice Salazar; Ning Jiang
Journal:  Sci Transl Med       Date:  2016-06-01       Impact factor: 17.956

10.  A single-chain antibody generation system yielding CAR-T cells with superior antitumor function.

Authors:  Toshiki Ochi; Masaki Maruta; Kazushi Tanimoto; Fumitake Kondo; Toshihiro Yamamoto; Mie Kurata; Hiroshi Fujiwara; Junya Masumoto; Katsuto Takenaka; Masaki Yasukawa
Journal:  Commun Biol       Date:  2021-03-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.